CARTESIAN THERAPEUTICS INC (RNAC)

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company...

RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024

RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the first quarte...

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Proposals approved at Company’s special meeting of stockholders held March 27, 2024...

RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023

RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the fourth quart...

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on...

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company...

Cartesian Therapeutics Announces New Employment Inducement Grant

GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the...

Cartesian Therapeutics Announces New Employment Inducement Grants

GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company...

SolarEdge Layoffs 2024: What to Know About the Latest SEDG Job Cuts

SolarEdge layoffs are coming for 16% of the company's workers as it prepares to reduce its total headcount by 900 employees.

Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?

Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday!

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm

/PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cartesian Therapeutics, Inc. (NASDAQ: RNAC) ("Cartesian"), formerly known as Selecta...

Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track...

Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up...

Selecta Biosciences Announces Merger with Cartesian Therapeutics

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly...